Accounting for tumor heterogeneity in the development of predictive biomarkers

Clinical Advances in Hematology and Oncology

Volumn 11, Issue 5, 2013, Pages 312-313

  Siu, Lillian L ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; BREAST CANCER; CELL HETEROGENEITY; CLINICAL TRIAL (TOPIC); COLON CANCER; GENE MUTATION; GENOMICS; HISTOLOGY; HUMAN; LUNG CANCER; ONCOLOGY; PERSONALIZED MEDICINE;

GENETIC HETEROGENEITY; GENOMICS; HUMANS; INDIVIDUALIZED MEDICINE; NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84878323916     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (4)

1. Sleijfer S, Bogaerts J, Siu LL. Designing transformative clinical trials in the cancer genome era. J Clin Oncol. 2013 April 15. [Epub ahead of print]
2. Tran B, Dancey JE, Kamel-Reid S, et al. Cancer genomics: technology, discovery, and translation. J Clin Oncol. 2012;30:647-660.
3. Wheeler HE, Maitland ML, Dolan ME, Cox NJ, Ratain MJ. Cancer pharmacogenomics: strategies and challenges. Nat Rev Genet. 2013;14:23-34.
4. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366:883-892.